Earnings ·
Reports $431.3M Q3 revenue and first-quarter profitability as Rezdiffra hits blockbuster status
MDGLMadrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals reported third-quarter 2026 net revenues of $431.3 million, a 50% increase year-over-year, driven by strong demand for its MASH treatment Rezdiffra. The company achieved its first quarter of profitability with net income of $55.4 million, or $1.83 per diluted share, compared to a net loss in the prior year period. Year-to-date net sales for Rezdiffra reached $1.1 billion, marking blockbuster status less than three years after launch. The company holds $961.8 million in cash and marketable securities as of September 30, 2026. Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).